Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

Primary Graft Failure Clinical Trial

Official title: Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

Status Recruiting

Clinical Trial Summary

This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure. The graft will consist of bone marrow or G-CSF mobilized peripheral blood from a haploidentical related donor. The source of stem cells will be determined by the transplant team based on factors such as patient's age, medical history, donor availability and will be according to the current University of Minnesota Blood and Marrow Transplantation Program selection guidelines.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Primary Graft Failure
• Secondary Graft Failure

• NCT number: NCT02161783
• Study type: Observational
• Source: Masonic Cancer Center, University of Minnesota
• Contact: Timothy Krepski
• Phone: 612-273-2800
• Email: tkrepsk1@fairview.org
• Status: Recruiting
• Start date: October 6, 2014
• Completion date: January 30, 2032